

Highly Enantioselective Conjugate Addition of Diethylzinc to Acyclic Enones with Fine-Tunable Phosphite-**Pyridine Ligands**

Huihui Wan, Yuanchun Hu, Yuxue Liang, Shuang Gao, Junwei Wang, Zhuo Zheng, and Xinquan Hu*

Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian 116023, People's Republic of China

xinquan@ms.dicp.ac.cn

Received May 6, 2003

Abstract: A new series of fine-tunable phosphite-pyridine (P,N) ligands derived from (*S*)-2-amino-2′-hydroxy-6,6′-dimethyl-1,1′-biphenyl and (*S*)-2-amino-2′-hydroxy-4,4′,6,6′ tetramethyl-1,1′-biphenyl was employed in Cu(I)-catalyzed conjugate addition of diethylzinc to acyclic enones. Excellent enantioselectivities (up to 98% ee) and highly catalytic activities were achieved for a variety of acyclic enones.

The 1,4-addition of organometallic reagents to conjugate enones is one of the most important methods for $carbon–carbon$ bond formation.¹ The Cu(I)-catalyzed enantioselective addition of Et₂Zn to enones has attracted much attention in the past decade, and a number of efficient copper catalysts with chiral ligands have been reported.2 Among those successful chiral ligands, phosphorus amidites by Feringa et al.3 and TADDOL-derived phosphites and biphenyl-derived phosphorus amidites by Alexakis et al.⁴ have shown remarkable enantioselectivities in the reaction of Et_2Zn addition to cyclic enones. Some diphosphine,⁵ diphosphite, 6 P,N ligands, 7 spirophosphoramidites, 8 and aminophosphine $\overline{9}$ are also ef-

10.1021/jo0345897 CCC: \$25.00 © 2003 American Chemical Society
Published on Web 09/24/2003

FIGURE 1. Chiral P,N ligands for Cu-catalyzed conjugate addition of Et₂Zn to chalcones.

ficient for this transformation. In contrast to the many successful chiral ligands for $Et₂Zn$ addition to cyclic enones, only a few chiral ligands are reported to be efficient for Et₂Zn addition to acyclic enones.¹⁰ Recently, Hoveyda et al.¹¹ have developed peptidic phosphines which have shown high enantioselectivities for various enone substrates. However, high enantioselectivities ($>95\%$ ee) are rarely reported for En₂Zn addition to chalcones $(1^{10c}$ and 2^{10a} in Figure 1).

In our previous paper, we developed chiral phosphitepyridine ligands derived from (*S*)-2-amino-2′-hydroxy-1,1′-binaphthyl (NOBIN) and (*S*)-2,2′-dihydroxy-1,1′ binaphthyl (BINOL) for Cu(I)-catalyzed Et_2Zn addition to chalcones.^{10a} High enantioselectivities and yields are obtained for a set of chalcones except for some electronrich substrates such as 4′-methyl and 4′-methoxy chalcones. The substrate limitation could probably be ascribed to the electron-deficiency of chiral phosphitepyridine ligands at the NOBIN moiety, which implied that the limitation could be improved by an electron-rich and electronic tunable ligand. In this paper, we synthesize a new series of phosphite-pyridine ligands **L1**-**4**, derived from relatively electron-rich biphenyl backbones, for $Cu(I)$ -catalyzed $Et₂Zn$ additions to acyclic enones in order to overcome the substrate limitation and verify the subtle alternating effects of electronic property of the chiral ligands. The new phosphite-pyridine ligands **L1**-**⁴** can be conveniently synthesized from our newly developed chiral biphenyl backbones **3**¹² in two steps (Scheme 1).^{10a}

Our previous studies showed that toluene is an appropriate solvent for the Cu(I)-catalyzed enantioselective conjugate additions of Et2Zn to chalcones (**1**).10a Thus **L1** and chalcone were chosen to optimize the reaction conditions. The conjugate addition of Et_2Zn to chalcone was

^{(1) (}a) Ojima, I. *Catalytic Asymmetric Synthesis*, 2nd ed.; VCH: Weinheim, Germany, 1999. (b) Jácobsen, E. Ň.; Pfaltz, A.; Yamamoto,
H., Eds.; *Comprehensive Asymmetric Catalysis I–III*; Springer: Berlin, H., Eds.; *Comprehensive Asymmetric Catalysis I– III*; Springer: Berlin,
Germany, 1999. (c) Hayashi, T.; Tomioka, K.; Yonemitsu, O. *Asymmetric Synthesis–Graphical Abstract and Experimental Methods,
metric Synthesis–Graphi* Kodansha: Tokyo, Japan, 1998. (d) Noyori, R. *Asymmetric Catalysis in Organic Synthesis*; Wiley: New York, 1994. (e) Perlmutter, P. *Conjugate Addition Reactions in Organic Synthesis*; Pergamon: Oxford, U.K., 1992.

⁽²⁾ For reviews, see: (a) Krause, N.; Roder. A. H. *Synthesis* **2001**, 171. (b) Feringa, B. L. *Acc. Chem. Res.* **2000**, *33*, 346. (c) Krause, N. *Angew. Chem., Int. Ed.* **1998**, *37*, 283. (d) Krause, N.; Gerold, A. *Angew. Chem., Int. Ed. Engl*. **1997**, *36*, 186. (e) Rossiter, B. E.; Swingle, H. M. *Chem. Rev*. **1992**, *92*, 771 and references therein.

^{(3) (}a) Martorell, A.; Naasz, R.; Feringa, B. L.; Pringle, P. G. *Tetrahedron*: *Asymmetry* **2001**, *12*, 2497. (b) Naasz, R.; Arnold, L. A.; Pineschi, M.; Keller, E.; Feringa, B. L. *J. Am. Chem. Soc.* **1999**, *121*, 1104. (c) Feringa, B. L.; Pineschi, M.; Arnold, L. A.; Imbos, R.; de Vries, A. H. M. *Angew. Chem., Int. Ed. Engl*. **1997**, *36*, 2620. (d) de Vries, A. H. M.; Mettsma, A.; Feringa, B. L. *Angew. Chem., Int. Ed. Engl*. **1996**, *35*, 2374.

^{(4) (}a) Alexakis, A.; Benhaim, C.; Rosset, S.; Humam, M. *J. Am. Chem. Soc*. **2002**, *124*, 5262. (b). Alexakis, A.; Benhaim, C. *Eur. J. Org. Chem.* **2002**, 3221. (c) Alexakis, A.; Vastra, J.; Burton, J.; Benhaim, C.; Mangeney, P. *Tetrahedron Lett.* **1998**, *39*, 7869. (5) Yamanoi, Y.; Imamoto, T. *J. Org. Chem.* **1999**, *64*, 2988.

^{(6) (}a) Reetz, M. T.; Gosberg, A.; Moulin, D. *Tetrahedron Lett.* **2002**, 43, 1189. (b) Liang, L.; Au-Yeung, T. T.-L.; Chan, A. S. C. *Org. Lett.* **2002**, 4, 3799. (c) Yan, M. S. C. *Org. Lett.* **2000**, 4, 3799. (c) Yan, M (e) Yan. M.; Yang, L.-W.; Wong, K.-Y.; Chan, A. S. C. *Chem. Commun*. **1999**, 11.

^{(7) (}a) Morimoto, T.; Yamaguchi, Y.; Suzuki, M.; Saitoh, A. *Tetrahedron Lett*. **2000**, *41*, 10025. (b) Escher, I. H.; Pfaltz, A. *Tetrahedron* **2000**, *56*, 2879.

⁽⁸⁾ Zhou, H.; Wang, W.-H.; Fu, Y.; Xie, J.-H.; Shi, W.-J.; Wang, L.-

X.; Zhou, Q.-L. *J. Org. Chem.* **2003**, *68*, 1582. (9) Mori, T.; Kosaka, K.; Nakagawa, Y.; Nagaoka, Y.; Tomioka, K. *Tetrahedron*: *Asymmetry* **1998**, *9*, 3175.

^{(10) (}a) Hu, Y.; Liang. X.; Wang, J.; Zheng, Z.; Hu, X. *J. Org. Chem.* **2003**, *68*, 4542. (b) Shintani, R.; Fu, G. C. *Org. Lett*. **2002**, *4*, 3699. (c) Hu, X.; Chen, H.; Zhang, X. *Angew. Chem., Int. Ed. Engl.* **1999**, *38*, 3518. (d) Alexakis, A.; Benhaim, C.; Fournioux, X.; van den Heuvel, A.; Leveque, J.-M., March S.; Rosset, S. *Synlett* **1999**, 1811. Leveque, J.-M. M

²⁰⁰³, *42*, 1276. (b) Degrado, S. J.; Mizutani, H.; Hoveyda, A. H. *J. Am. Chem. Soc.* **2002**, *124*, 13362. (c) Mizutani, H.; Degrado, S. J.; Hoveyda, A. H. *J. Am. Chem. Soc*. **2002**, *124*, 779. (d) Degrado, S. J.; Mizutani, H.; Hoveyda, A. H. *J. Am. Chem. Soc*. **2001**, *123*, 755.

⁽¹²⁾ Liang, Y.; Gao, S.; Wan, H.; Wang, J.; Chen, H.; Zheng, Z.; Hu, X. *Tetrahedron*: *Asymmetry* **2003**, *14*, 1267.

TABLE 1. Cu-Catalyzed Enantioselective 1,4-Conjugate Addition of Et₂Zn to Chalcone^{*a*}

	Ph	$[Cu(CH_3CN)_4]BF_4 / L1$ Et ₂ Zn, Toluene		\star Ph	(1)
entry	T (°C)	time (h)	yield ^b $(\%)$	ee^c (%)	config ^d
	10	12	79	79	\boldsymbol{S}
2	0	12	71	87	\mathcal{S}_{0}
3	-10	12	73	90	\mathcal{S}
4	-20	12	83	93	\mathcal{S}
5	-30	12	75	88	\mathcal{S}_{0}
6	-20	6	82	93	\mathcal{S}
7	-20	3	80	94	S

^a The reaction was carried out for 1.5 mL of toluene, chalcone $(0.5 \text{ mmol})/[Cu(CH_3CN)_4]BF_4/L1 = 1/0.01/0.025, 0.70 \text{ mL of Et}_2Zn$ (1.1 M in toluene). *^b* Isolated yield. *^c* The ee values were determined by HPLC with a ChiralPak-AD column. *^d* The absolute configuration was assigned by comparison of the optical rotation with reported data.

carried out in toluene in the presence of $Cu(CH_3CN)_4BF_4$ (1 mol %) and **L1** (2.5 mol %). The results are summarized in Table 1. As can be seen, the reaction temperature has a remarkable influence on the enantioselectivity of the reaction (entries $1-5$). The best ee and yield are obtained when the reaction proceeded at -20 °C. The reaction time has a marginal effect on the yield as little difference is observed when the time varies from 3 to 12 h (entries 4, 6, and 7).

We thus used **L1**-**⁴** as the ligands for Cu-catalyzed enantioselective conjugate addition of Et₂Zn to parasubstituted (Me, MeO, Cl) chalcones (**2**) (entries 1-7, Table 2). The reactions were carried out at -20 °C in toluene with 1.5 equiv of $Et₂Zn$ as the reagent. As shown in Table 2, ligands **L1**-**⁴** provided over 95% ee for 4-substituted and electron-deficient 4′-substituted (Cl)

chalcones (entries 2, 4, 6, and 7, Table 2). Ligand **L4** gave the best enantioselectivities for all chalcone substrates. Although a 6-methyl group of the pyridine moiety of the ligand was helpful for obtaining high enantioselectivities in most cases (column **L2** vs column **L1**, column **L4** vs column **L3**, Table 2), methyl groups at 4,4′-positions of biphenyl moiety were beneficial to improve enantioselectivity for 4′-methoxy chalcone as substrate (entry 5, Table 2, 95% ee from **L4** and 87% ee from **L2** vs 74% ee from ligand 2^{10a}). The different behaviors of ligands $L1-4$ and ligand **2**10a suggested the effects of the tunable electronic property of chiral ligands on the conjugate additions.

To extend the substrate scope of this transformation, the conjugate addition of Et₂Zn to *trans*-4-aryl-3-buten-2-one substrates has been studied (entries 8-11, Table 2). Interestingly, the more electron-rich but less sterically hindered ligand **L3** gave the best ee's for all *trans*-4-aryl-3-buten-2-one substrates. Up to 96% ee has been obtained for conjugate addition of *trans*-4-(4-chlorophenyl)-3-buten-2-one (entry 11, Table 2). Compared to other ligands, **L3** has also shown the best chemical yields for those substrates.

In summary, we have developed a new series of finetunable phosphite-pyridine ligands **L1**-**⁴** from (*S*)-biphenyl backbones and (*S*)-BINOL. The electron-rich and sterically hindered ligand **L4** has been successfully applied in Cu-catalyzed conjugate addition of Et_2Zn to various chalcone substrates and up to 98% ee has been obtained. An electron-rich but less sterically hindered ligand **L3** provides best results for *trans*-4-aryl-3-buten-2-one substrates.

Experimental Section

Synthesis of the Amides:10a (*S***)**-**(**-**)-2-(2-Pyridinylcarboxamido)-2**′**-hydroxy-6,6**′**-dimethyl-1,1**′**-biphenyl (4a).** The amide **4a** (0.916 g, 96%) was prepared from 0.443 g of picolinic acid (3.6 mmol) and **3a** (0.639 g, 3.0 mmol) and isolated as a white solid: mp 150-151 °C; $[\alpha]^{12}$ _D -16.2 (*c* 0.36, CHCl₃); ¹H NMR (DMSO- \dot{d}_6) *δ* 1.83 (s, 3H), 1.97 (s, 3H), 6.85–6.90 (m, 2H), 7.10 (d, $J = 7.6$ Hz, 1H), 7.22 (t, $J = 7.6$ Hz, 1H), 7.31 (t, $J = 8.0$ Hz, 1H), $7.50 - 7.54$ (m, 1H), $7.96 - 8.00$ (m, 1H), 8.10 (d, $J = 7.6$ Hz, 1H), 8.29 (d, $J = 4.4$ Hz, 1H), 8.38 (d, $J = 8.0$ Hz, 1H), 9.34 (s, 1H), 9.77 (s, 1H); 13C NMR (DMSO-*d*6) *δ* 19.2, 19.64, 113.4, 116.7, 121.1, 121.8, 121.9, 125.3, 126.9, 127.4, 127.9, 129.1, 135.3, 136.9, 137.5, 138.3, 148.2, 149.1, 154.8, 161.0; HR-MS calcd for $C_{20}H_{18}N_2O_2$ 318.1369, found 318.1374.

(*S***)**-**(**-**)-2-(6-Methyl-2-pyridinylcarboxamido)-2**′**-hydroxy-6,6**′**-dimethyl-1,1**′**-biphenyl (4b).** The amide **4b** (0.734 g, 94%) was prepared from 0.386 g of 6-methylpicolinic acid (2.8 mmol) and **3a** (0.500 g, 2.3 mmol) and isolated as a white solid: mp 157-158 °C; $[\alpha]^{12}$ _D -17.3 (*c* 0.26, CHCl₃); ¹H NMR (DMSO- d_6) *^δ* 1.85 (s, 3H), 1.99 (s, 3H), 2.23 (s, 3H), 6.88-6.93 (m, 2H), 7.08 $(d, J = 7.6 \text{ Hz}, 1H), 7.24 (t, J = 8.0 \text{ Hz}, 1H), 7.30 (t, J = 8.0 \text{ Hz},$ 1H), 7.38 (d, $J = 8.8$ Hz, 1H), 7.83-7.89 (m, 2H), 8.44 (d, $J =$ 8.0 Hz, 1H), 9.33 (s, 1H), 10.06 (s, 1H); 13C NMR (DMSO-*d*6) *δ* 19.2, 19.7, 23.5, 113.4, 115.7, 118.6, 121.1, 121.9, 125.0, 126.4, 127.5, 129.1, 135.5, 136.9, 137.7, 138.4, 148.3, 154.9, 156.8, 160.9; HR-M, calcd for C21H20N2O2 332.1526, found 332.1520.

(*S***)-(**-**)-2-(2-Pyridinylcarboxamido)-2**′**-hydroxy-4,4**′**,6,6**′ **tetramethyl-1,1**′**-biphenyl (4c).** The amide **4c** (0.915 g, 88%) was prepared from 0.443 g of picolinic acid (3.6 mmol) and **3b** $(0.723 \text{ g}, 3.0 \text{ mmol})$ and isolated as a white solid: mp $118-119$ ${}^{\circ}C$; [α]¹²_D -3.0 (*c* 0.226, CHCl₃); ¹H NMR (DMSO-*d*₆) *δ* 1.79 (s, 3H), 1.92 (s, 3H), 2.29 (s, 3H), 2.34 (s, 3H), 6.67 (d, $J = 7.2$ Hz, 2H), 6.91 (s, 1H), $7.51 - 7.54$ (m, 1H), 7.98 (t, $J = 7.6$ Hz, 1H), 8.09 (d, $J = 7.6$ Hz, 1H), 8.19 (s, 1H), 8.31 (d, $J = 4.0$ Hz, 1H),

entry	\mathbb{R}^1	\mathbb{R}^2	$L1^{b,c}$		$L2^{b,c}$		$L3^{b,c}$		$L4^{b,c}$		
			yield $(\%)$	ee (%)	yield (%)	ee (%)	yield $(\%)$	ee (%)	yield $(\%)$	ee (%)	config ^d
	Ph	Ph	79	94	76	97	81	96	83	97	\boldsymbol{S}
2	$4-Me-C6H4$	Ph	88	95	77	97	90	96	84	97	$+^e$
3	Ph	4 -Me-C ₆ H ₄	72	90	82	96	87	92	82	97	$+^e$
4	$4-MeO-C6H4$	Ph	74	94	68	97	85	96	76	98	\boldsymbol{S}
5	Ph	$4-MeO-C6H4$	32	75	23	87	58	84	57	95	$-e$
6	4 -Cl-C ₆ H ₄	Ph	74	96	57	94	85	97	77	97	$+^e$
7	Ph	4 -Cl-C ₆ H ₄	87	96	77	96	85	97	78	97	$-e$
8	Ph	Me	20	81	14	20	67	90	24	52	$+^e$
9	$4-Me-C6H4$	Me	24	88	12	54	47	90	28	53	$+^e$
10	$4-MeO-C6H4$	Me	24	85		40	44	90	21	58	$+e$
11	4 -Cl-C $_6$ H ₄	Me	7	93	4	56	70	96	34	75	$+^e$

TABLE 2. Cu-Catalyzed Enantioselective 1,4-Conjugate Addition of Et2Zn to Acyclic Enones*^a*

^a The reaction was carried out at -20 °C for 6 h in 3 mL of toluene (substrate (1.0 mmol)/[Cu(CH3CN)4]BF4/**L1**-**L4**/Et2Zn) 1/0.01/ 0.025/1.5. *^b* Isolated yield. *^c* The ee values were determined by HPLC with a ChiralPak-AD column or by GC with a Supelco *γ*-DEX 225 column. *^d* The absolute configuration was assigned by comparison of the optical rotation with reported data. *^e* Sign of the optical rotation of addition product.

9.14 (s, 1H), 9.74 (s, 1H); 13C NMR (DMSO-*d*6) *δ* 19.2, 19.6, 21.0, 21.2, 113.9, 117.2, 118.9, 121.7, 121.9, 125.1, 126.0, 126.9, 135.4, 136.3, 136.8, 137.3, 138.1, 138.3, 148.3, 149.2, 154.8, 160.9; HR-MS calcd for $C_{22}H_{22}N_2O_2$ 346.1682, found 346.1685.

(*S***)**-**(**-**)-2-(6-Methyl-2-pyridinylcarboxamido)-2**′**-hydroxy-4,4**′**,6,6**′**-tetramethyl-1,1**′**-biphenyl (4d).** The amide **4d** (0.728 g, 97%) was prepared from 0.341 g of 6-methylpicolinic acid (2.5 mmol) and **3b** (0.500 g, 2.1 mmol) and isolated as a white solid: mp 178-179 °C; [α]²⁶_D -1.6 (*c* 0.322, CHCl₃); ¹H NMR (DMSO*d*6) *δ* 1.80 (s, 3H), 1.96 (s, 3H), 2.23 (s, 3H), 2.29 (s, 3H), 2.34 (s, 3H), 6.70 (s, 2H), 6.89 (s, 1H), 7.36-7.41 (m, 1H), 7.83-7.87 (m, 2H), 8.27 (s, 1H), 9.12 (s, 1H), 10.03 (s, 1H); 13C NMR (DMSO*d*6) *δ* 19.2, 19.6, 21.0, 21.3, 23.2, 114.0, 116.2, 118.5, 119.0, 121.9, 124.6, 125.7, 126.3, 135.5, 136.4, 136.8, 137.5, 138.1, 138.4, 148.4, 154.9, 156.7, 160.7; HR-MS calcd for $C_{23}H_{24}N_2O_2$ 360.1839, found 360.1829.

Synthesis of the Ligands:10a L1. Typical Procedure. Amide **4a** (318.4 mg, 1.0 mmol), 465.4 mg of (*S*)-Feringa's phosphorus-amidite ligand **⁵** (1.3 mmol), and 10 mL of toluene were added to a 50 mL air-free Schlenk flask with a reflux condenser under an argon atmosphere. After 12 h of refluxing, the reaction was complete (detected by TLC) and the mixture cooled to room temperature. The solvent was removed under reduced pressure, the residue was purified by column chromatagraphy on 30 g of silica gel and eluted with EtOAc/hexanes $(1/5-1/2)$ to afford white foamy solid. Recrystallization with CH_2Cl_2 /heptane and drying in vacuo provided 601 mg of ligand **L1** (95%) as a white solid: mp 99-123 °C; $[\alpha]^{16}$ 302 (*c* 0.53, THF); ¹H NMR (CD₂Cl₂) δ 2.02 (s, 6H), 6.83 (d, J = 8.8 Hz, 1H), 7.14-7.28 (m, 8H), 7.33-7.47 (m, 5H), 7.72-7.78 (m, 2H), 7.84- 7.95 (m, 3H), 8.09 (d, $J = 7.6$ Hz, 1H), 8.15 (d, $J = 4.8$ Hz, 1H), 8.55 (d, $J = 8.0$ Hz, 1H), 9.72 (s, 1H); ¹³C NMR (CD₂Cl₂) δ 20.2, 20.8, 118.2, 119.6, 119.7, 122.4, 122.46, 122.53, 123.2, 124.9, 125.6, 125.9, 126.4, 126.8, 127.0, 127.3, 127.5, 127.6, 129.1, 129.3, 130.2, 130.5, 131.1, 132.0, 132.3, 133.0, 133.4, 137.2, 138.1, 138.4, 140.5, 147.7, 148.2, 148.5, 150.4, 150.6, 162.4; 31P NMR *δ* 145.34; HR-MS calcd for C40H29N2O4P 632.1866, found 632.1874.

L2. The ligand **L2** (577 mg, 89%) was prepared from amide **4b** (332.0 mg, 1.0 mmol) and **5** (465.4 mg, 1.3 mmol) according to the same procedure as used for **L1** and isolated as a white solid: mp 99-125 °C; [α]¹⁶_D 305 (*c* 0.558, THF); ¹ H NMR (CD_2Cl_2) *δ* 2.03 (s, 3H), 2.04 (s, 3H), 2.16 (s, 3H), 6.79 (d, $J =$ 8.8 Hz, 1H), 7.09-7.28 (m, 8H), 7.34-7.48 (m, 5H), 7.61 (t, *^J*) 7.6 Hz, 1H), 7.76 (d, $J = 8.8$ Hz, 1H), 7.83-7.95 (m, 4H), 8.65 (d, $J = 8.0$ Hz, 1H), 9.97 (s, 1H); ¹³C NMR (CD₂Cl₂) δ 20.2, 20.8, 24.4, 117.4, 119.3, 119.61, 119.62, 122.4, 122.6, 123.2, 124.9, 125.6, 125.9, 126.1, 126.4, 126.8, 127.0, 127.2, 127.5, 127.7, 129.1, 129.4, 130.2, 130.5, 131.1, 132.0, 132.3, 132.9, 133.4, 137.4, 138.2, 140.6, 147.7, 148.2, 149.8, 150.5, 157.7, 162.4; 31P NMR *δ* 145.42; HR-MS calcd for $C_{41}H_{31}N_2O_4P$ 646.2023, found 646.2027.

L3. The ligand **L3** (949 mg, 95%) was prepared from amide **4c** (519.0 mg, 1.5 mmol) and **5** (698.1 mg, 2.0 mmol) according to the same procedure as used for **L1** and isolated as a white solid: mp 92–133 °C; [α]¹⁶_D 261 (*c* 0.508, THF); ¹H NMR
(CD₂Cl₂) *δ* 1.981 (s, 3H), 1.984 (s, 3H), 2.43 (s, 3H), 2.52 (s, 3H), 6.84 (d, $J = 8.8$ Hz, 1H), $7.00 - 7.07$ (m, 3H), $7.16 - 7.29$ (m, 5H), 7.34-7.43 (m, 3H), 7.72-7.78 (m, 2H), 7.85-7.96 (m, 3H), 8.10 (d, $J = 7.6$ Hz, 1H), 8.18 (d, $J = 4.0$ Hz, 1H), 8.44 (s, 1H), 9.71 (d, *J* = 7.6 Hz, 1H), 8.18 (d, *J* = 4.0 Hz, 1H), 8.44 (s, 1H), 9.71 (s, 1H); ¹³C NMR (CD₂Cl₂) *δ* 20.2, 20.8, 21.7, 22.3, 118.7, 120.2, 120.3, 122.4, 122.5, 122.7, 123.3, 124.4, 124.9, 125.6, 125.9, 126.7, 126.8, 127.0, 127.3, 127.5, 128.4, 129.1, 130.4, 131.1, 132.0, 132.3, 133.0, 133.4, 137.2, 138.1, 138.3, 139.2, 140.1, 140.4, 147.8, 148.3, 148.6, 150.5, 150.8, 162.3; 31P NMR *δ* 145.25; HR-MS calcd for $C_{42}H_{33}N_2O_4P$ 660.2180, found 660.2173.

L4. The ligand **L4** (606 mg, 90%) was prepared from amide **4d** (360.3 mg, 1.0 mmol) and **5** (465.4 mg, 1.3 mmol) according to the same procedure as used for **L1** and isolated as a white solid: mp $91-132$ °C; $[\alpha]^{16}$ 262 (c 0.474, THF); ¹H NMR (CD2Cl2) *δ* 1.99 (s, 3H), 2.02 (s, 3H), 2.17 (s, 3H), 2.43 (s, 3H), 2.52 (s, 3H), 6.78 (d, $J = 8.8$ Hz, 1H), 6.99-7.12 (m, 4H), 7.16-7.30 (m, 4H), 7.34-7.43 (m, 3H), 7.61 (t, $J = 7.6$ Hz, 1H), 7.76 (d, $J = 8.8$ Hz, 1H), $7.84 - 7.96$ (m, 4H), 8.52 (s, 1H), 9.96 (s, 1H); ¹³C NMR (CD₂Cl₂) δ 20.2, 20.8, 21.6, 22.3, 24.2, 117.9, 119.3, 120.3, 122.4, 122.7, 123.3, 123.9, 124.9, 125.6, 125.9, 126.3, 126.8, 127.0, 127.2, 127.5, 128.5, 129.1, 130.4, 131.1, 132.0, 132.3, 133.0, 133.4, 137.4, 138.2, 139.3, 140.4, 147.8, 148.3, 149.9, 150.6, 157.6, 162.2; ³¹P NMR δ 145.39; HR-MS calcd for C₄₃H₃₅N₂O₄P 674.2336, found 674.2354.

General Procedure for Asymmetric 1,4-Conjugate Addition: Preparation of Catalyst. L1 (126.4 mg, 0.20 mmol), 25.2 mg of $[Cu(CH_3CN)_4]BF_4$ (0.08 mmol), and 16 mL of toluene were added to a 50 mL air-free Schlenk flask under an argon atmosphere. After 30 min of stirring at room temperature, the solvent was stripped off in vacuo, $8 \text{ mL of } CH_2Cl_2$ was added to the flask, and the catalyst solution was used for eight separated conjugate addition reactions.

Asymmetric 1,4-Conjugate Addition. Chalcone substrate (1 mmol) and 1 mL of the above-prepared catalyst solution were added to a flame-dried Schlenk tube under an argon atmosphere. After the solvent had been stripped off, 3 mL of toluene was added. The slurry was stirred at room temperature for 10 min and then cooled to the desired temperature. After the slurry had been stirred for 15 min, 1.4 mL of Et_2Zn (1.1 M in toluene, 1.5 mol equiv) was added slowly. The resulting mixture was stirred at that temperature for 6 h. Four milliliters of 5% hydrochloric acid was added to quench the reaction. The mixture was allowed to warm to room temperature, and then 15 mL of diethyl ether was added. The organic layer was washed with 5 mL of saturated $NaHCO₃$ and 5 mL of brine and then dried over anhydrous Na2SO4. The solvent was removed under reduced pressure, and

JOC Note

the residue was purified by column chromatagraphy on silica gel and eluted with EtOAc/hexanes $(1/40-1/20)$ to afford the addition product.

Acknowledgment. This work was supported by the National Science Foundation of China (29933050) and the Young Faculty Research Fund of DICP.

Supporting Information Available: General Experimental Section, HPLC and GC conditions for ee values, and spectra of **4a**-**d**, **L1**-**⁴** (1H NMR, 13C NMR, and 31P NMR). This material is available free of charge via the Internet at http://pubs.acs.org.

JO0345897